Search
Talacotuzumab
go.drugbank.com/drugs/DB14796InvestigationalTalacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.
AMY-101
go.drugbank.com/drugs/DB14803InvestigationalAMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3.
Plitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is also of interest as a potential treatment for some leukemias.
Pegcrisantaspase
go.drugbank.com/drugs/DB16281InvestigationalPegcrisantaspase is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young
Fentanyl
go.drugbank.com/drugs/DB00813ApprovedIllicitInvestigationalVet approvedFentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L66...
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalNogapendekin alfa is a human IL-15N72D variant. It is one of the active ingredients in Anktiva, a combination product also containing inbakicept, where a single inbakicept is complexed with two nogapendekin alfa components. This combinat...
Eptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigationalEptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human ...
Epoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...
Nelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigationalNelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), in both adult and pediatric pa...
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]